Strain Name:

B6.Cg-Tg(tetO-DTA)1Gfi/J

Stock Number:

008468

Order this mouse

Availability:

Repository- Live

Common Names: B6.tet-DTA;    
These tet-DTA mice express diphtheria toxin A (DTA) under the control of a tetracycline operator (tetO; also called tetracycline-responsive element (TRE) or tet-operator) and a cytomegalovirus minimal promoter, and may be useful in generating bi-transgenic mutant mice for the inducible deletion of specific groups of cells.

Description

Strain Information

Type Congenic; Transgenic;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Additional information on Congenic nomenclature.
Mating SystemHomozygote x Homozygote         (Female x Male)   19-NOV-09
Specieslaboratory mouse
GenerationN6F2 (29-SEP-14)
Generation Definitions
 
Donating Investigator IMR Colony,   The Jackson Laboratory

Description
These tet-DTA transgenic mice express diphtheria toxin A (DTA) under the control of a tetracycline operator (tetO; also called tetracycline-responsive element (TRE) or tet-operator) and a cytomegalovirus minimal promoter. When bred with another mouse expressing reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA), tissue diphtheria toxin A expression can be regulated with the tetracycline analog doxycycline (dox) in the resulting double mutant offspring. These tet-DTA mice may be useful in generating bi-transgenic mutant mice for the reversible, inducible deletion of specific groups of cells.

For example, when bred to a strain expressing tTA in cardiac myocytes (see Stock No. 003170 for example), this mutant mouse strain may be useful in studies of human cardiomyopathies.

When bred to a strain expressing tTA in pancreatic beta cells (see Stock No. 008250 for example), this mutant mouse strain may be useful in studies of diabetes and beta cell regeneration.

When bred to a strain expressing tTA in pancreatic beta cells (see Stock No. 008250) as well as a strain with a tamoxifen inducible Cre recomibinase (see Stock No. 008122 and a strain with a cre inducible alkaline phosphatase (see Stock No. 003919 , this mutant mouse strain may be useful in studies of diabetes and beta cell regeneration.

When bred to a strain expressing tTA in cardiac tissue (Tg(Myh6-tTA)6Smbf, see Stock No. 017770 for example), this mutant mouse strain may be useful in studies of arrhythmogenesis.

Development
The tet-DTA transgene was designed with a diphtheria toxin A (DTA) sequence under the control of heptamerized tetracycline operator (tetO; also called tetracycline-responsive element (TRE) or tet-operator) sequences and a cytomegalovirus minimal promoter. This transgene was injected into fertilized B6CBAF2 mouse eggs. Founder animals were bred to outbred ICR mice and then made homozygous prior to arrival at The Jackson Laboratory (as Stock No. 008168). Upon arrival, some mice were backcrossed to C57BL/6J for at least 5 generations to generate this congenic strain (Stock No. 008468).

Control Information

  Control
   000664 C57BL/6J
 
  Considerations for Choosing Controls

Related Strains

Strains carrying   Tg(tetO-DTA)1Gfi allele
008755   STOCK Tg(Ins2-rtTA)2Efr Tg(teto-DTA)1Gfi/J
008168   STOCK Tg(tetO-DTA)1Gfi/J
View Strains carrying   Tg(tetO-DTA)1Gfi     (2 strains)

Strains carrying other alleles of Dta
008617   B6(A)-Tg(OPN1LW-DT)1Mame/J
007942   B6.Cg-Isl2tm1Arbr/J
017949   B6.FVB-Tg(CD207-Dta)312Dhka/J
006576   B6.FVB-Tg(GNAT2-Dta)98Wwk/J
002384   FVB/N-Tg(UcpDta)1Kz/J
006331   STOCK Gt(ROSA)26Sortm1(DTA)Jpmb/J
View Strains carrying other alleles of Dta     (6 strains)

Strains carrying other alleles of tetO
008079   129S-Ppargtm2Yba/J
016178   B6(Cg)-Tg(tetO-Cry2)3Jt/J
016176   B6(Cg)-Tg(tetO-Per2)2Jt/J
023757   B6(Cg)-Tg(tetO-tetX,lacZ)1Gogo/UmriJ
009602   B6.129S4(Cg)-Kcnn2tm2Jpad/J
009603   B6.129S4-Kcnn3tm1Jpad/J
023910   B6.Cg-Col1a1tm1(tetO-Lin28a)Gqda/J
023911   B6.Cg-Col1a1tm2(tetO-LIN28B)Gqda/J
023912   B6.Cg-Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/J
017983   B6.Cg-Col1a1tm9(tetO-Dnmt3b_i1)Jae Gt(ROSA)26Sortm1(rtTA*M2)Jae/J
014588   B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm6(tetO-MSI2)Jae/J
023749   B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae Tg(tetO-Pou5f1,-Sox2,-Klf4,-Myc)1Srn/J
014648   B6.Cg-Gt(ROSA)26Sortm37(H1/tetO-RNAi:Taz)Arte/ZkhuJ
006361   B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J
016998   B6.Cg-Tg(TetO-Axin1,EGFP)TA6Cos/J
003762   B6.Cg-Tg(tetFosb)4468Nes/J
007051   B6.Cg-Tg(tetO-APPSwInd)102Dbo/Mmjax
007052   B6.Cg-Tg(tetO-APPSwInd)107Dbo/Mmjax
007049   B6.Cg-Tg(tetO-APPSwInd)885Dbo/Mmjax
007618   B6.Cg-Tg(tetO-Arntl)1Jt/J
017555   B6.Cg-Tg(tetO-CALY)5Cber/J
024114   B6.Cg-Tg(tetO-CHRM4*)2Blr/J
008277   B6.Cg-Tg(tetO-Clockm1Jt)CL57Jt/J
017791   B6.Cg-Tg(tetO-Hamp)2181Nca/J
009344   B6.Cg-Tg(tetO-Ifng)184Pop/J
009136   B6.Cg-Tg(tetO-Kcnj2,lacZ)1Gogo/J
013583   B6.Cg-Tg(tetO-LRRK2)C7874Cai/J
020652   B6.Cg-Tg(tetO-Mif)279Aren/J
017331   B6.Cg-Tg(tetO-Ppp3ca*)11255Kndl/J
017332   B6.Cg-Tg(tetO-Ppp3ca*)13967Kndl/J
017330   B6.Cg-Tg(tetO-TAg*)175Kndl/J
006234   B6.Cg-Tg(tetO-cre)1Jaw/J
005738   B6.FVB-Tg(tetO-EGFP,-Tgfbr2)8Mcle/J
021025   B6;129-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm1(tetO-cre)Haho/J
006911   B6;129-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm2(tetO-Pou5f1)Jae/J
011001   B6;129S4-Col1a1tm1(tetO-Pou5f1,-Klf4,-Sox2,-Myc)Hoch/J
016836   B6;129S4-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm7(tetO-HIST1H2BJ/GFP)Jae/J
012433   B6;C3-Tg(ACTA1-rtTA,tetO-cre)102Monk/J
002709   B6;C3-Tg(TettTALuc)1Dgs/J
023598   B6;C3-Tg(tetO-AIMP2)630Tmd/J
023642   B6;C3-Tg(tetO-AIMP2)634Tmd/J
016841   B6;C3-Tg(tetO-TARDBP)12Vle/J
014650   B6;C3-Tg(tetO-TARDBP*)4Vle/J
012450   B6;D2-Tg(tetO-SNCA)1Cai/J
008344   B6;DBA-Tg(Fos-tTA,Fos-EGFP*)1Mmay Tg(tetO-lacZ,tTA*)1Mmay/J
024742   B6;DBA-Tg(tetO-GCaMP6s)2Niell/J
024088   B6;FVB-Tg(tetO-AML1/ETO)8Dzh/J
008082   B6;SJL-Tg(Tagln-tTA)1Mrab Tg(tetO-Mcpt1)1Mrab/J
010575   B6;SJL-Tg(tetO-Egfr*)2-9Jek/J
010577   B6;SJL-Tg(tetO-Erbb2*)8-4Jek/J
002621   B6;SJL-Tg(tetop-lacZ)2Mam/J
006004   B6C3-Tg(tetO-APPSwInd)885Dbo/Mmjax
016976   B6C3-Tg(tetO-SNCA*A53T)33Vle/J
018913   B6N.Cg-Tg(tetO-GFP,-lacZ)G3Rsp/J
006244   C.Cg-Tg(tetO-cre)1Jaw/J
017719   C3HeB/FeJ-Tg(tetO-TAg)1Efr/J
017955   C57BL/6-Tg(Gfap-rtTA,tetO-MAOB,-lacZ)1Jkan/J
025487   C57BL/6-Tg(tetO-Aimp1)29872Mcla/J
005706   C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J
006618   C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J
017613   C57BL/6-Tg(tetO-Cdkn1b)1Scpr/J
013729   C57BL/6-Tg(tetO-EDN1,-lacZ)9Mhus/J
016260   C57BL/6-Tg(tetO-Fbxl21)38Jt/J
016179   C57BL/6-Tg(tetO-Fbxl21*)11Jt/J
010713   C57BL/6-Tg(tetO-GFP/tetX)5696Stl/J
013728   C57BL/6-Tg(tetO-NOS2,-lacZ)240iMhus/J
016181   C57BL/6-Tg(tetO-Nr1d1)1Schb/J
016581   C57BL/6J-Tg(tetO-Btrc*)1Jt/J
008278   C57BL/6J-Tg(tetO-Clock)1Jt/J
024898   C57BL/6J-Tg(tetO-EGFP/Rpl10a)5aReij/J
016580   C57BL/6J-Tg(tetO-Usf1)2Jt/J
021065   FVB(C)-Tg(tetO-Npc1/YFP)1Mps/J
017542   FVB-Tg(Myh6/tetO-ATP2B4)1Jmol/J
016571   FVB-Tg(Myh6/tetO-Gata6)2Jmol/J
014155   FVB-Tg(Myh6/tetO-Itpr1)22.3Jmol/J
014153   FVB-Tg(Myh6/tetO-Itpr2)3.11Jmol/J
014154   FVB-Tg(Myh6/tetO-Itpr2)4.9Jmol/J
012684   FVB-Tg(Myh6/tetO-POSTN)22.1Jmol/J
010580   FVB-Tg(Myh6/tetO-PRKCA*)1Jmk/J
013156   FVB-Tg(tetO-CDK5R1*)1Vln/J
013777   FVB-Tg(tetO-Cacna1g)1Jmol/J
013778   FVB-Tg(tetO-Cacnb2)1Jmol/J
013779   FVB-Tg(tetO-Cacnb2)2Jmol/J
013780   FVB-Tg(tetO-Cib1)1Jmol/J
010578   FVB-Tg(tetO-Dusp6)1Jmol/J
017333   FVB-Tg(tetO-Gnai2*,-lacZ)382Kndl/J
008685   FVB-Tg(tetO-Kdr*)4377.5Rwng/J
023397   FVB-Tg(tetO-Lmnb1)AF1Yfu/J
015815   FVB-Tg(tetO-MAPT*P301L)#Kha/JlwsJ
008695   FVB-Tg(tetO-MET)23Rwng/J
012387   FVB-Tg(tetO-Ppargc1a)1Dpk/J
012385   FVB-Tg(tetO-Ppargc1b)7Dpk/J
022979   FVB-Tg(tetO-Thbs4)17.7Jmol/J
006439   FVB-Tg(tetO/CMV-KRAS*G12C)9.1Msmi/J
019038   FVB.Cg-Tg(tetO-GLI1)10Rup/Mmjax
019039   FVB.Cg-Tg(tetO-KLF4)32831Rup/Mmjax
008244   FVB.Cg-Tg(tetO-cre)1Jaw/J
012459   FVB/N-Tg(Myh6*/tetO-Capn1)L2Gwd/J
005941   FVB/N-Tg(tetO-Aurkb,lacZ)41Kra/J
006202   FVB/N-Tg(tetO-BCR/ABL1)2Dgt/J
014547   FVB/N-Tg(tetO-Fasl)BDepa/J
025672   FVB/N-Tg(tetO-Fgfr2b/Igh)1.3Jaw/J
019376   FVB/N-Tg(tetO-MYC)36aBop/J
026278   FVB/N-Tg(tetO-Ube3a*1)1Svd/J
026279   FVB/N-Tg(tetO-Ube3a*2)884Svd/J
022938   FVB/N-Tg(tetO-Wnt5a)17Rva/J
003315   FVB/N-Tg(tetORo1-lacZ)3Conk/J
005076   NOD.Cg-Tg(tetO-EGFP/FADD)1Doi/DoiJ
006999   STOCK Dbttm1Geh Tg(Cebpb-tTA)5Bjd Tg(tetO-DBT)A1Geh/J
011004   STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/J
011011   STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm4(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/J
011013   STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm5(tetO-Pou5f1,-Klf4,-Myc)Jae/J
017596   STOCK Gt(ROSA)26Sortm1.1(rtTA,EGFP)Nagy Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN2*delta7)4299Ahmb Tg(tetO-SMN2,-luc)#aAhmb/J
017597   STOCK Gt(ROSA)26Sortm1.1(rtTA,EGFP)Nagy Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN2*delta7)4299Ahmb Tg(tetO-SMN2,-luc)#bAhmb/J
025671   STOCK Gt(ROSA)26Sortm1.1(rtTA,EGFP)Nagy Tg(tetO-Fgf10)1Jaw/SpdlJ
024854   STOCK Tg(Camk2a-tTA)1Mmay Tg(tetO-MAPT*P301L)#Kha/J
012477   STOCK Tg(Myh6*/tetO-GCaMP2)1Mik/J
016572   STOCK Tg(Myh6/tetO-Gata4)1Jmol/J
014544   STOCK Tg(tetO-ABL1*P242E*P249E)CPdav/J
014093   STOCK Tg(tetO-CHRM3*)1Blr/J
008790   STOCK Tg(tetO-DISC1*)1001Plet/J
017755   STOCK Tg(tetO-GCAMP2)12iRyu/J
024509   STOCK Tg(tetO-Gata6)1Abl/J
016970   STOCK Tg(tetO-HCV)1Mlch/Mmjax
005104   STOCK Tg(tetO-HIST1H2BJ/GFP)47Efu/J
005699   STOCK Tg(tetO-Ipf1,EGFP)956.6Macd/J
005728   STOCK Tg(tetO-Ipf1,lacZ)958.1Macd/J
012441   STOCK Tg(tetO-LRRK2*G2019S)E3Cai/J
017918   STOCK Tg(tetO-MAML1*/EGFP)2Akar/J
017599   STOCK Tg(tetO-SMN2,-luc)#aAhmb/J
017600   STOCK Tg(tetO-SMN2,-luc)#bAhmb/J
012442   STOCK Tg(tetO-SNCA*A53T)E2Cai/J
006224   STOCK Tg(tetO-cre)1Jaw/J
017906   STOCK Tg(tetO-hop/EGFP,-COP4/mCherry)6Kftnk/J
012345   STOCK Tg(tetO-tdTomato,-Syp/EGFP*)1.1Luo/J
012449   STOCK Tg(teto-LRRK2)C7874Cai/J
View Strains carrying other alleles of tetO     (136 strains)

Additional Web Information

Tet Expression Systems

Phenotype

Phenotype Information

View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

The following phenotype relates to a compound genotype created using this strain.
Contact JAX® Services jaxservices@jax.org for customized breeding options.

Tg(CAG-Bgeo/ALPP)1Lbe/0 Tg(Ins2-cre/ERT)1Dam/0 Tg(Ins2-rtTA)2Efr/0 Tg(tetO-DTA)1Gfi/0

        involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA   (conditional)
  • endocrine/exocrine gland phenotype
  • increased pancreatic beta cell number
    • tamoxifen injections during last 10 days of doxycycline treatment labels surviving beta cells with human placental alkaline phosphatase; labeling results indicate that majority or all regenerated beta cells are derived from surviving beta cells, rather than from non-beta cells or stem cells   (MGI Ref ID J:127412)
  • homeostasis/metabolism phenotype
  • hyperglycemia
    • treatment of newborn mice with doxycycline for 45 days results in diabetes development   (MGI Ref ID J:127412)

Tg(Ins2-rtTA)2Efr/0 Tg(tetO-DTA)1Gfi/0

        involves: C57BL/6 * CBA
  • endocrine/exocrine gland phenotype
  • *normal* endocrine/exocrine gland phenotype
    • average size of regenerating beta cells is same as original cells   (MGI Ref ID J:127412)
    • abnormal pancreas morphology
      • pancreatic insulin content is reduced by ~85%; after doxycycline withdrawal, pancreatic insulin level return to near control levels   (MGI Ref ID J:127412)
      • abnormal pancreatic beta cell morphology
        • frequency of insulin-positive, glucagons-positive beta cells increases from 1:5500 in controls to 1:1000 beta cells in diabetic transgenic mice   (MGI Ref ID J:127412)
        • permitting doxycycline-treated mice to recover in presence of immunosupressants Sirolimus and Tacrolimus (SirTac) significantly reduces beta cell proliferation and beta cell mass does not increase as it does in absence of immunosupressants; blood glucose levels in treated mice fail to normalize as they do in controls treated with SirTac   (MGI Ref ID J:127412)
        • decreased pancreatic beta cell number
          • 70-80% of beta cells are lost in doxycycline-treated 5-week old double-transgenic mice relative to controls   (MGI Ref ID J:127412)
          • similar results are obtained when beta cells are ablated between birth and five weeks of age; beta cell mass normalizes within ~15 weeks of doxycycline withdrawal   (MGI Ref ID J:127412)
        • increased pancreatic beta cell number
          • rate of beta cell apoptosis in recovering mice is not different from controls, but beta cell proliferation is increased 2-3-fold within 48 hours of onset of beta cell ablation; this increased proliferation rate is maintained for several weeks   (MGI Ref ID J:127412)
      • disorganized pancreatic islets
        • treatment of four-week old mice with doxycycline for 1 week results in severely disrupted islet architecture with non-beta cells at the core of shriveled islets rather than beta cells   (MGI Ref ID J:127412)
        • after withdrawal of doxycycline, normalization of islet architecture occurs in ~90% of islets   (MGI Ref ID J:127412)
  • homeostasis/metabolism phenotype
  • *normal* homeostasis/metabolism phenotype
    • peripheral insulin sensitivity after beta cell regeneration is similar to controls after doxycycline withdrawal, beta cell mass in transgenic mice increases to levels comparable to wild-type   (MGI Ref ID J:127412)
    • improved glucose tolerance
      • after more than 8 months without doxycycline, glucose tolerance starts to recover   (MGI Ref ID J:127412)
      • similar results are obtained when beta cells are ablated between birth and five weeks of age; beta cell mass normalizes within ~15 weeks of doxycycline withdrawal   (MGI Ref ID J:127412)
      • mice that showed severe, chronic or adult-onset (starting at 4 months) hyperglycemia spontaneously normalized blood glucose levels and beta-cell mass after doxycycline withdrawal   (MGI Ref ID J:127412)
    • increased circulating glucose level
      • blood glucose levels of treated mice are elevated to 300-600 mg/dl making the mice overtly diabetic; after withdrawal of doxycycline, blood glucose levels return to normal level   (MGI Ref ID J:127412)
      • mice that showed severe, chronic or adult-onset (starting at 4 months) hyperglycemia spontaneously normalized blood glucose levels and beta-cell mass after doxycycline withdrawal   (MGI Ref ID J:127412)
      • hyperglycemia
        • blood glucose levels are elevated to 300-600 mg/dl; after doxycycline withdrawal, remission of hyperglycemia occurs such that fed and fasting glucose levels normalize   (MGI Ref ID J:127412)
        • mice that showed severe, chronic or adult-onset (starting at 4 months) hyperglycemia spontaneously normalized blood glucose levels and beta-cell mass after doxycycline withdrawal   (MGI Ref ID J:127412)
  • cellular phenotype
  • increased apoptosis
    • widespread pancreatic beta cell apoptosis is seen within 48 hours of doxycycline treatment of double-transgenic mice, but no apoptosis is observed in single transgenic littermates   (MGI Ref ID J:127412)

Tg(Myh6-tTA)6Smbf/0 Tg(tetO-DTA)1Gfi/0

        involves: C57BL/6 * CBA
  • mortality/aging
  • complete lethality throughout fetal growth and development
    • in absence of maternal supplementation with tetracycline (Tc) during gestation, no binary (or double) transgenic offspring are born, whereas gestational or perinatal suppressive Tc treatment results in Mendelian numbers of binary offspring (22%)   (MGI Ref ID J:128617)
    • genotypic analysis at times throughout gestation show that death of double transgenic embryos occurs between 10.5 days post conception (dpc) and fetal day 19   (MGI Ref ID J:128617)
  • partial embryonic lethality during organogenesis
    • in absence of maternal supplementation with tetracycline (Tc) during gestation, no binary (or double) transgenic offspring are born, whereas gestational or perinatal suppressive Tc treatment results in Mendelian numbers of binary offspring (22%)   (MGI Ref ID J:128617)
    • genotypic analysis at times throughout gestation show that death of double transgenic embryos occurs between 10.5 days post conception (dpc) and fetal day 19   (MGI Ref ID J:128617)
  • premature death
    • when Tc treatment is withdrawn after birth, mortality results with median survival time of 37 days (earliest time of death is 12 days after withdrawal of Tc, latest death is 77 days); death occurs suddenly with no indication of illness   (MGI Ref ID J:128617)
  • cardiovascular system phenotype
  • abnormal heart atrium morphology
    • atrial tissue destruction is seen in some hearts   (MGI Ref ID J:128617)
  • abnormal heart ventricle morphology
    • ventricles show patchy fibrosis following Tc withdrawal   (MGI Ref ID J:128617)
    • dilated heart ventricle
      • in some hearts, prominent ventricular dilatation is observed following Tc withdrawal   (MGI Ref ID J:128617)
  • abnormal impulse conducting system conduction
    • at 1 month after tetracycline withdrawal, a subset of isolated-perfused hearts display markedly disturbed activation profiles, with either disorganized conduction or evidence of block during pacing   (MGI Ref ID J:128617)
    • majority of even mildly diseased hearts are arrhythmogenic   (MGI Ref ID J:128617)
  • cardiac fibrosis
    • ventricles show mild patchy fibrosis to severe fibrosis following Tc withdrawal   (MGI Ref ID J:128617)
  • decreased myocardial fiber number
    • hearts show evidence of mild to severe myocyte loss   (MGI Ref ID J:128617)
  • increased cardiomyocyte apoptosis
    • some hearts display severe cell loss following tetracycline withdrawal   (MGI Ref ID J:128617)
  • irregular heartbeat
    • following Tc withdrawal, a variety of arrhythmias are detected in double transgenic mice which show increased propensity to develop reentrant tachycardia, including atrial fibrillation, pauses, and complex ventricular ectopy such as runs of ventricular tachycardia   (MGI Ref ID J:128617)
    • majority of even mildly diseased hearts are arrhythmogenic   (MGI Ref ID J:128617)
    • atrial fibrillation
      • following tetracycline withdrawal, atrial fibrillation occurs in some mice   (MGI Ref ID J:128617)
  • ventricular tachycardia
    • at 1 month after Tc withdrawal, most isolated-perfused hearts display either spontaneous or inducible ventricular tachycardia, including both sustained and nonsustained runs of ventricular tachycardia with some episodes lasting J:128617)
  • muscle phenotype
  • decreased myocardial fiber number
    • hearts show evidence of mild to severe myocyte loss   (MGI Ref ID J:128617)
  • increased cardiomyocyte apoptosis
    • some hearts display severe cell loss following tetracycline withdrawal   (MGI Ref ID J:128617)
  • homeostasis/metabolism phenotype
  • atrial thrombosis
    • mural thrombus formation is prominent in atrial tissue in some animals following Tc withdrawal   (MGI Ref ID J:128617)
  • cellular phenotype
  • increased cardiomyocyte apoptosis
    • some hearts display severe cell loss following tetracycline withdrawal   (MGI Ref ID J:128617)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Cell Biology Research
Genes Regulating Growth and Proliferation

Neurobiology Research
Tet Expression System
      tTA/rtTA Responsive Strains

Research Tools
Cancer Research
      Tetop Tet System
Cardiovascular Research
      Tetop Tet System
Cell Biology Research
Genetics Research
      Mutagenesis and Transgenesis
      Mutagenesis and Transgenesis: Tetop Tet System
Neurobiology Research
      Tetop Tet System
Reproductive Biology Research
      Tetop Tet System
Tet Expression Systems
      tTA/rtTA Responsive Strains
Toxicology Research

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Tg(tetO-DTA)1Gfi
Allele Name transgene insertion 1, Glenn I Fishman
Allele Type Transgenic (Inducible, Inserted expressed sequence)
Common Name(s) tet-DTA; tetODTA/+;
Strain of Origin(C57BL/6 x CBA)F2
Site of Expressionpancreatic beta cells
Expressed Gene Dta, Diphtheria toxin A chain,
Promoter tetO, tet operator,
General Note Phenotypic Similarity to Human Syndrome: Narcolepsy J:211045, J:211046
Molecular Note A transgenic construct was created, containing diphtheria toxin A sequence (DTA) under the control of heptamerized tetracycline operator, tetO sequences fused to a cytomegalovirus minimal promoter. [MGI Ref ID J:128617]
 
 

Genotyping

Genotyping Information

Genotyping Protocols

Tg(tetO-DTA)1Gfi, QPCR
Tg(tetO-DTA)1Gfi, Standard PCR
tg(teto-DTA)1Gfi/j,

MELT



Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Lee P; Morley G; Huang Q; Fischer A; Seiler S; Horner JW; Factor S; Vaidya D; Jalife J; Fishman GI. 1998. Conditional lineage ablation to model human diseases. Proc Natl Acad Sci U S A 95(19):11371-6. [PubMed: 9736743]  [MGI Ref ID J:128617]

Nir T; Melton DA; Dor Y. 2007. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 117(9):2553-61. [PubMed: 17786244]  [MGI Ref ID J:127412]

Stanger BZ; Tanaka AJ; Melton DA. 2007. Organ size is limited by the number of embryonic progenitor cells in the pancreas but not the liver. Nature 445(7130):886-91. [PubMed: 17259975]  [MGI Ref ID J:118596]

Additional References

Tg(tetO-DTA)1Gfi related

Black SW; Morairty SR; Chen TM; Leung AK; Wisor JP; Yamanaka A; Kilduff TS. 2014. GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy. J Neurosci 34(19):6485-94. [PubMed: 24806675]  [MGI Ref ID J:211046]

Castello NA; Nguyen MH; Tran JD; Cheng D; Green KN; LaFerla FM. 2014. 7,8-Dihydroxyflavone, a small molecule TrkB agonist, improves spatial memory and increases thin spine density in a mouse model of Alzheimer disease-like neuronal loss. PLoS One 9(3):e91453. [PubMed: 24614170]  [MGI Ref ID J:215124]

Chi W; Wu E; Morgan BA. 2013. Dermal papilla cell number specifies hair size, shape and cycling and its reduction causes follicular decline. Development 140(8):1676-83. [PubMed: 23487317]  [MGI Ref ID J:195121]

Gheryani N; Coffelt SB; Gartland A; Rumney RM; Kiss-Toth E; Lewis CE; Tozer GM; Greaves DR; Dear TN; Miller G. 2013. Generation of a novel mouse model for the inducible depletion of macrophages in vivo. Genesis 51(1):41-9. [PubMed: 22927121]  [MGI Ref ID J:207362]

Porat S; Weinberg-Corem N; Tornovsky-Babaey S; Schyr-Ben-Haroush R; Hija A; Stolovich-Rain M; Dadon D; Granot Z; Ben-Hur V; White P; Girard CA; Karni R; Kaestner KH; Ashcroft FM; Magnuson MA; Saada A; Grimsby J; Glaser B; Dor Y. 2011. Control of pancreatic beta cell regeneration by glucose metabolism. Cell Metab 13(4):440-9. [PubMed: 21459328]  [MGI Ref ID J:172243]

Tabuchi S; Tsunematsu T; Black SW; Tominaga M; Maruyama M; Takagi K; Minokoshi Y; Sakurai T; Kilduff TS; Yamanaka A. 2014. Conditional ablation of orexin/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function. J Neurosci 34(19):6495-509. [PubMed: 24806676]  [MGI Ref ID J:211045]

Wei W; Zeve D; Wang X; Du Y; Tang W; Dechow PC; Graff JM; Wan Y. 2011. Osteoclast progenitors reside in the peroxisome proliferator-activated receptor gamma-expressing bone marrow cell population. Mol Cell Biol 31(23):4692-705. [PubMed: 21947280]  [MGI Ref ID J:178880]

Yamasaki TR; Blurton-Jones M; Morrissette DA; Kitazawa M; Oddo S; LaFerla FM. 2007. Neural stem cells improve memory in an inducible mouse model of neuronal loss. J Neurosci 27(44):11925-33. [PubMed: 17978032]  [MGI Ref ID J:127469]

Yeung ST; Myczek K; Kang AP; Chabrier MA; Baglietto-Vargas D; Laferla FM. 2014. Impact of hippocampal neuronal ablation on neurogenesis and cognition in the aged brain. Neuroscience 259:214-22. [PubMed: 24316470]  [MGI Ref ID J:207913]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           FGB27

Colony Maintenance

Breeding & HusbandryMutant mice were bred to C57BL/6J mice for may generations to establish this congenic strain. When maintaining the live congenic colony, homozygous mice may be bred together. Of note, homozygosity was determined by qPCR.
Mating SystemHomozygote x Homozygote         (Female x Male)   19-NOV-09
Diet Information LabDiet® 5K52/5K67

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $239.00Female or MaleHomozygous for Tg(tetO-DTA)1Gfi  
Price per Pair (US dollars $)Pair Genotype
$478.00Homozygous for Tg(tetO-DTA)1Gfi x Homozygous for Tg(tetO-DTA)1Gfi  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $310.70Female or MaleHomozygous for Tg(tetO-DTA)1Gfi  
Price per Pair (US dollars $)Pair Genotype
$621.40Homozygous for Tg(tetO-DTA)1Gfi x Homozygous for Tg(tetO-DTA)1Gfi  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Control Information

  Control
   000664 C57BL/6J
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.8)